Viewing Study NCT02030834

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:28 AM
Ignite Modification Date: 2026-03-11 @ 2:09 AM
Study NCT ID: NCT02030834
Status: COMPLETED
Last Update Posted: 2023-06-22
First Post: 2014-01-07
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Sponsor: University of Pennsylvania
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas View
Keywords: